Table 6. Immunogenicity of HPV4 vaccine (Gardasil^®) among males 16 to 26 years (n=2025) (114).

Assay (cLIA v2.0)	HPV4 (n=2025)
	Geometric mean titre (GMT)	95% CI	Seroconversion rate	95% CI
Anti-HPV type 6
Day 1	<7	<7-<7	0.0	0-0.3
Month 7	446.0	422-474	98.9	98-99
Month 24	80.3	76-85	90.8	89-93
Anti-HPV type 11
Day 1	<8	<8-<8	0.0	0-0.3
Month 7	624.2	594-656	99.2	98-100
Month 24	94.5	90-100	95.6	94-97
Anti-HPV type 16
Day 1	<11	<11-<11	0.0	0-0.3
Month 7	2402.5	2271-2542	98.8	98-99
Month 24	347.8	329-367	99.3	99-100
Anti-HPV type 18
Day 1	<10	<10-<10	0.0	0-0.3
Month 7	402.2	380-426	97.4	96-98
Month 24	38.7	36-41	62.3	59-65